Tanja Giesen1, Sebastian Sanduleanu1, Tim L Th A Jansen2. 1. Department of Rheumatology, VieCuri MC, Venlo, The Netherlands. 2. Department of Rheumatology, VieCuri MC, Venlo, The Netherlands. tjansen@viecuri.nl.
Abstract
INTRODUCTION: Erosive Hand OsteoArthritis (EHOA) is a common rheumatological problem. We aim to determine characteristics of EHOA patients: comorbidities, radiographic erosivity and pain experienced after being diagnosed, in order to find which of these are potentially relevant in upcoming interventional trials. METHOD: Retrospective analysis of EHOA patients within the electronic database in one centre, with a telephone interview on pain as experienced even exceeding 12 months after being diagnosed. RESULTS: Eighty-four non-academic EHOA patients were found: 89% females (median age 69 years), 11% males (similar age distribution). Kellgren-Lawrence (KL) erosivity scores in both sexes were comparable; DIPs scored higher than PIP's. Comorbid conditions were crystal-induced arthritis, rheumatoid arthritis (RA) and psoriatic arthritis (PsA) in 8%, 5% and 1%, respectively; seropositivity for rheumatoid factor and anti-citrullinated protein antibodies in 8% and 1% respectively. Pain worst experienced often exceeded a visual analogue score of 5.0, but was unrelated to the total KL score. Some pain reduction was reached with non-steroidals (perorally/transcutaneously) as deduced from continued use in 1 in 3. CONCLUSIONS: In many EHOA patients, there is an unmet need regarding the treatment of pain, which per se was not directly correlated with erosivity score. Future studies may be designed considering the aforementioned characteristics, acting on the inflammatory process resulting in PIP/DIP erosions, with the exclusion of RA and PsA in order to get a clean study on EHOA. Several studies with monoclonal antibodies have been performed but demonstrated ineffectivity on the outcome of pain. Hope glooms with the arrival of innovative small molecules that may reach EHOA target cells. Key Points • Erosive handOA is a common problem in non-academic rheumatology; it is often associated with significant pain in both sexes exceeding a VASpain of 5.0 even years after being diagnosed; 1 in 3 found some relief in non-steroidals perorally/transcutaneously. • Future studies will have to focus on (episodic) inflammatory hand OA resulting in proven erosivity (EHOA) located in PIP plus DIP joints and may have to exclude comorbid active crystal-induced arthritis as well as rheumatoid/psoriatic arthritis and possibly even RF/ACPA seropositivity in order to get a clean study on EHOA. • As several big monoclonals have failed in EHOA, we may have to search for promising new drugs within the group of small molecules. These will have to show a significant pain-reducing effect and preferably also a disease-modifying osteoarthritis drug (DMOAD) effect.
INTRODUCTION: Erosive Hand OsteoArthritis (EHOA) is a common rheumatological problem. We aim to determine characteristics of EHOA patients: comorbidities, radiographic erosivity and pain experienced after being diagnosed, in order to find which of these are potentially relevant in upcoming interventional trials. METHOD: Retrospective analysis of EHOA patients within the electronic database in one centre, with a telephone interview on pain as experienced even exceeding 12 months after being diagnosed. RESULTS: Eighty-four non-academic EHOA patients were found: 89% females (median age 69 years), 11% males (similar age distribution). Kellgren-Lawrence (KL) erosivity scores in both sexes were comparable; DIPs scored higher than PIP's. Comorbid conditions were crystal-induced arthritis, rheumatoid arthritis (RA) and psoriatic arthritis (PsA) in 8%, 5% and 1%, respectively; seropositivity for rheumatoid factor and anti-citrullinated protein antibodies in 8% and 1% respectively. Pain worst experienced often exceeded a visual analogue score of 5.0, but was unrelated to the total KL score. Some pain reduction was reached with non-steroidals (perorally/transcutaneously) as deduced from continued use in 1 in 3. CONCLUSIONS: In many EHOA patients, there is an unmet need regarding the treatment of pain, which per se was not directly correlated with erosivity score. Future studies may be designed considering the aforementioned characteristics, acting on the inflammatory process resulting in PIP/DIP erosions, with the exclusion of RA and PsA in order to get a clean study on EHOA. Several studies with monoclonal antibodies have been performed but demonstrated ineffectivity on the outcome of pain. Hope glooms with the arrival of innovative small molecules that may reach EHOA target cells. Key Points • Erosive handOA is a common problem in non-academic rheumatology; it is often associated with significant pain in both sexes exceeding a VASpain of 5.0 even years after being diagnosed; 1 in 3 found some relief in non-steroidals perorally/transcutaneously. • Future studies will have to focus on (episodic) inflammatory hand OA resulting in proven erosivity (EHOA) located in PIP plus DIP joints and may have to exclude comorbid active crystal-induced arthritis as well as rheumatoid/psoriatic arthritis and possibly even RF/ACPA seropositivity in order to get a clean study on EHOA. • As several big monoclonals have failed in EHOA, we may have to search for promising new drugs within the group of small molecules. These will have to show a significant pain-reducing effect and preferably also a disease-modifying osteoarthritis drug (DMOAD) effect.
Authors: Ida Kristin Haugen; David T Felson; Martin Englund; Ke Wang; Piran Aliabadi; Ali Guermazi; Frank W Roemer; Tuhina Neogi Journal: Ann Rheum Dis Date: 2012-06-23 Impact factor: 19.103
Authors: Féline P B Kroon; Marion C Kortekaas; Annelies Boonen; Stefan Böhringer; Monique Reijnierse; Frits R Rosendaal; Naghmeh Riyazi; Mirian Starmans; Franktien Turkstra; Jende van Zeben; Cornelia F Allaart; Margreet Kloppenburg Journal: Lancet Date: 2019-11-11 Impact factor: 79.321
Authors: Margreet Kloppenburg; Roberta Ramonda; Klaus Bobacz; Wing-Yee Kwok; Dirk Elewaut; Tom W J Huizinga; Féline P B Kroon; Leonardo Punzi; Josef S Smolen; Bert Vander Cruyssen; Ron Wolterbeek; Gust Verbruggen; Ruth Wittoek Journal: Ann Rheum Dis Date: 2018-10-03 Impact factor: 19.103
Authors: Stanley B Cohen; Susanna Proudman; Alan J Kivitz; Francis X Burch; John P Donohue; Deborah Burstein; Yu-Nien Sun; Christopher Banfield; Michael S Vincent; Liyun Ni; Debra J Zack Journal: Arthritis Res Ther Date: 2011-07-29 Impact factor: 5.156
Authors: X Chevalier; P Ravaud; E Maheu; G Baron; A Rialland; P Vergnaud; C Roux; Y Maugars; D Mulleman; C Lukas; D Wendling; P Lafforgue; D Loeuille; V Foltz; P Richette Journal: Ann Rheum Dis Date: 2014-05-09 Impact factor: 19.103
Authors: Viola Klück; Tim L Th A Jansen; Matthijs Janssen; Antoaneta Comarniceanu; Monique Efdé; Isak W Tengesdal; Kiki Schraa; Maartje C P Cleophas; Curtis L Scribner; Damaris B Skouras; Carlo Marchetti; Charles A Dinarello; Leo A B Joosten Journal: Lancet Rheumatol Date: 2020-04-08